HF Advisory Group Boosts Amgen Stake by 341%

Institutional investor increases holdings in biotech giant during Q4 2025

Apr. 2, 2026 at 11:13am

Got story updates? Submit your updates here. ›

HF Advisory Group LLC significantly increased its stake in Amgen Inc. (NASDAQ: AMGN) during the fourth quarter of 2025, boosting its holdings by 341.8% to 9,756 shares. The firm's investment in the medical research company was valued at $3.19 million as of its latest SEC filing.

Why it matters

Amgen is one of the world's largest independent biotechnology companies, with a focus on developing innovative human therapeutics. Institutional investors closely monitor the company's performance and ownership changes can signal broader market trends or shifts in investor sentiment.

The details

According to the 13F filing, HF Advisory Group added 7,548 shares of Amgen to its portfolio during Q4 2025. The firm now owns a total of 9,756 shares of the medical research company's stock. Amgen's share price has seen steady growth in recent quarters, driven by the continued success of its core product pipeline and the company's ongoing investments in research and development.

  • HF Advisory Group filed its 13F report for Q4 2025 on April 2, 2026.

The players

HF Advisory Group LLC

An institutional investment firm that manages a diversified portfolio of equity and fixed-income securities.

Amgen Inc.

A global biotechnology company that discovers, develops, manufactures and delivers human therapeutics to treat serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in HF Advisory Group's Amgen holdings suggests the firm sees strong long-term potential in the biotech company's product pipeline and growth prospects. This move aligns with broader trends of institutional investors closely monitoring the performance of major pharmaceutical and biotechnology firms.